Covid19 Vaccine Orientation

1. REPUBLIC OF THE PHILIPPINES
DEPARTMENT OF HEALTH

2. National COVID-19 Vaccine Deployment &
Vaccination Program
Mayrjun Lo R. Jacosalem, RN
Nurse II – Department of Health, Talakag

3. COVID-19 Vaccine Deployment and
Vaccination Program
General Objective: To save lives and mitigate the impact of COVID-19 pandemic
Specific Objectives:
1. To launch a national vaccination program against COVID - 19
2. To provide free and effective, high quality vaccines against SARS-CoV-2, prioritizing
the most-at-risk and most-vulnerable populations

4. Department of Health, Philippines 4

5. Guiding Principles
National Ownership
Shared Responsibility and
Partnership
Integration
Innovation
The national government shall ensure primary ownership and responsibility for
establishing good governance and provision of quality and effective immunization services
for all.
COVID-19 immunization is an individual, community, societal and government
responsibility that cuts across borders and sectors.
The COVID-19 immunization services shall be fully integrated into the country’s health
systems and eventually to the regular immunization services.
Adaption and incorporation of the scientific evidence on COVID-19 vaccine and
immunization is vital to ensure effective implementation of immunization services.
Public Good
The COVID-19 vaccines shall be a public good, and shall be made available to all members
of the society.

6. Determining the Priority Eligible Population
● Assumptions
● At least 60-70% of the population is needed to have immunity to break the chain of transmission, either
through natural immunity or vaccination (WHO, Aug 2020).
● Philippine Population 111,046,913
● Decision Points:
○ To aim for HERD IMMUNITY by vaccinating at least 60-70% of the population (65 - 77 million
Filipinos)
■ Australia: To vaccinate 95% of the population.
■ Japan: To vaccinate all citizens by mid 2021.
■ South Korea: To vaccinate at least 60% of the population.
○ To prioritize certain population groups (based on risk and vulnerability).
■ US, Canada, Belgium, UK: To vaccinate priority groups.

7. Prioritization
● Direct reduction of
morbidity and mortality.
● Maintenance of most
critical essential services.
Primary Goal:
● Substantially control
transmission
● Minimize disruption of
social, economic and
security functions.
Secondary Goal:
Tertiary Goal:
● Resumption to near
normal.

8. Who will be vaccinated?
Eligible Population Definition of Terms
1. Frontline Health Workers
● a) Public and private health facilities (Hospitals, TRCs and TTMFs
● b) Public health workers (all RHU/CHO personnel; PHO, PDOHO, CHD and CO field
workers) and LGU contact tracers
2: Indigent Senior Citizens
● ALL indigent senior citizens registered and as determined by the Department of Social
Welfare and Development
3: Remaining Senior Citizens
● ALL senior citizens (not categorized as indigent) registered and as determined by the
Department of Social Welfare and Development
4: Remaining Indigent Population
● ALL indigent population as determined by the Department of Social Welfare and
Development
5: Uniformed personnel
● All enlisted uniformed personnel in active services under the:
○ Armed Forces of the Philippines
○ Philippine National Police
○ Philippine Coast Guard
○ Bureau of Fire Protection
○ Citizen Armed Force Geographical Unit

9. Who is the priority population?
Order of Prioritization Groups of Priority Eligible Population
1st Priority Frontline health workers
2nd Priority Indigent senior citizens
3rd Priority Remaining senior citizens
4th Priority Remaining indigent population
5th Priority Uniformed personnel (PNP, AFP, PCG, BFP, CAFGU)
6th Priority Teachers and school health workers (public and private)
7th Priority All government workers (national and local government)
8th Priority Essential workers in agriculture, food industry, transportation and tourism)
9th Priority Sociodemographic groups at significantly higher risk other than the senior citizens and
indigent population (PDLs, PWDs, Filipinos living in high-density areas)
10th Priority Overseas Filipino Workers (OFWs)
11th Priority Other remaining workforce
12th Priority Students

10. Senior Citizen
1. On the Day of Registration
a. The line list of senior citizens is obtained from the DSWD.
b. The personnel administration office identifies the indigent senior
citizens for screening.
c. Identified senior citizens shall proceed to the designated health facility
for screening.
d. The senior citizen, or companion, fills out the electronic profile form if
they passed the screening assessment, given all criteria are met.
Otherwise, the senior citizen shall be given notice for non-qualification
and health advice, as needed.

11. 2. On the Day of Vaccination
a. All pre-screened senior citizens who had given consent shall be identified
by the designated health worker for re-screening.
b. The identified senior citizen shall proceed to the personnel clinic for re-
screening.
c. The electronic profile form of the eligible senior citizen is updated if they
passed the re-screening assessment, given all criteria are met. Otherwise,
the senior citizen shall be given notice for non-qualification and health
advice, as needed.
d. The electronic profile of the eligible senior citizen shall be updated

12. e. The eligible senior citizen shall be requested for the re-affirmation of the
consent form.
f. The eligible senior citizen shall be administered with the vaccine.
g. Vaccine recipient’s QR code shall be updated with post-vaccination
instruction and issued with Certificate of Vaccination with the date of 1st
dose vaccination. Note: If needed, the administration of 2nd dose shall be
conducted a re-screening procedure.
3. On the Day of Second Dose of Vaccination, if necessary
a. All senior citizens administered with first dose vaccination shall be
identified by the designated health worker, for second dose of vaccination,
if necessary.

13. b. The identified senior citizen shall proceed to the personnel clinic for re-
screening.
c. The senior citizen, or companion shall update their electronic profile form
if they passed the re-screening assessment, given all criteria are met.
Otherwise, the senior citizen shall be given notice for non-qualification
and health advice, as needed.
d. The eligible senior citizen shall be requested for the re-affirmation of the
consent form.
e. The eligible senior citizen shall be administered with the second dose of
the vaccine.
f. Vaccine recipient’s QR code shall be updated with post-vaccination
instruction and issued with Certificate of Vaccination with the date of 2nd
dose vaccination.

15. Symptoms may appear 2 to 14 days after exposure to the virus.
Symptoms may appear 2 to 14 days after exposure to the virus.
Symptoms
COVID-19 disease is caused by a novel coronavirus called SARS-CoV-2. The virus is
mainly transmitted from person to person via droplets, contact, and fomites. It is
transmitted when an infected person/individual coughs, sneezes, or exhales
producing droplets of saliva containing the COVID-19 virus. COVID-19 primarily
affects the lungs but can also affect other organs.
I. Basic facts about COVID-19

17. Preparing the Vaccination Site
Entrance Exit
Registration
Area (2)
Screening
Area (2)
Counselling
and Final
Consent
Area (1)
Vaccination
Area (1)
Post-
Vaccination
Monitoring Area
(2)
QR and
Data
System
Waiting Area
QR and
Data
System
QR and
Data
System
Projector
or TV BP, Temp,
PE,
Present
Hx
VT1
VT2
VT3
BP, Temp,
PE,
Present
Hx
BP, Temp,
PE,
Present
Hx
Vaccine,
syringe,
SCB
BP, AEFI Kit,
Ambulance
Vaccine,
syringe,
SCB
Vaccine,
syringe,
SCB
S
A
S
A
S
A
S
A
S
A
S
A
S
A
S
A
S
A
S
A
S
A
Entrance Exit
Vaccination Proper Post - Vaccination Area
~12-17 minutes 30 minutes - 1 hour
3-5 minutes 5 minutes 3-5 minutes 1-2 minutes

18. Inactivated or weakened virus vaccines:
● Uses a form of the virus that has been inactivated or weakened so it doesn’t cause
disease, but still generates an immune response.
Protein-based vaccines:
● Use harmless fragments of proteins or protein shells that mimic the COVID-19
virus to safely generate an immune response.
Viral Vector vaccines:
● Use a virus that has been genetically engineered so that it can’t cause disease, but
produces coronavirus proteins to safely generate an immune response.
RNA and DNA vaccines:
● A cutting-edge approach that uses genetically engineered RNA or DNA to generate
a protein that itself safely prompts an immune response.
How do COVID-19 Vaccines work?

21. SINOV
AC SINOPHARM
A
BHAR
AT

25. Source: Sec.Carlito Galvez
Logistics Summit

26. Speed, Scale, Access
3
6

27. Name of
Vaccine
Vaccine
platform
Cold Chain
Requirement Vaccination
Site
Age
Route of
Administratio
n
Interval Dose Type Appearance
Novovax
Protein Sub-
unit
2-8 °C (shelf
life
undetermined)
Upper Outer
Arm
Adults, Older
Adults (18-84
y/o)
Alternating IM
(Deltoid)
Injection
0, 21 days
2 doses at 0.5
ml
? ?
Oxford/
Astrazeneca
Viral vector 2-8 °C
Upper Outer
Arm (Deltoid)
18 y/o and
above
IM 0,28 days
2 doses at 0.5
ml
? ?
Pfizer/
BionTech
RNA
-70°C or -80°C
(2years)
Upper Outer
Arm (Deltoid)
≥12 y/o and
above
IM
0,28 days (3
weeks apart)
2 doses at 0.3
ml
Frozen
multiple
dose vials +
diluent
white to off white
suspension before
and after dilution;
may contain
white to off-white
opaque
amorphous
particles.
Information on COVID-19 Vaccines

28. Name of
Vaccine
Vaccine
platform
Cold Chain
Requirement
Vaccination
Site
Age
Route of
Administratio
n
Interval Dose Type Appearance
Moderna RNA
70 or -80°C
- 20°C (10
months)
Upper Outer
Arm (Deltoid)
ALL IM 0, 28 days
2 doses at 0.5
ml
Frozen
multiple dose
vials
white to off-
white
suspension;
may contain
white or
translucent
product-
related
particulates.
Sinovac Inactivated
2-8°C (5
months);
25°C (42
days);
37°C (28 days)
Upper Outer
Arm (Deltoid)
18-59 y/o IM 0, 28 days
2 doses at 0.5
ml
? ?
Gamaleya
Non-
replicating
viral vector
-16°C
Upper Outer
Arm (Deltoid)
18-60 y/0 IM 0, 21 days
2 doses at 0.5
ml
? ?
Information on COVID-19 Vaccines

29. Contraindications, Exclusion, and Inclusion Criteria for COVID-19 Vaccination
Absolute contraindications:
● History of anaphylaxis or a
severe hypersensitivity reaction
during previous immunization
● Known allergy to vaccine
component
Other contraindications specific to brand:
● History of COVID-19 infection (+ RT-PRC Test)
● Exposure to COVID-19 case (+IgG or IgM)
● Comorbidities (Hypertension, CVA, Heart, Liver
and Kidney disease, Diabetes Mellitus,
Immunodeficient state, Tuberculosis, Allergy,
Steroid use, History of epilepsy)
● Blood donation / recipient)
Other exclusion criteria: Pregnant women, lactating women; Men and women unwilling to
use contraception during treatment phase; Not a participant of another clinical trial; recipient
of other vaccine 3 months prior

30. Department of Health, Philippines
THANK YOU!

31. REFERENCES
World Health Organization - Global manual on surveillance of adverse events following
immunization
National Epidemiology Center, Department of Health - Adverse Events Following
Immunization (AEFI)
A Manual of Procedure for Surveillance and Response to AEFI (2014)
DOH AO: 2016-0006: Revised Guidelines on Surveillance and Response to Adverse Events
Following Immunization